Evox Therapeutics

36 articles about Evox Therapeutics

• Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platform

  8/9/2023

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the publication in Nature Communications of Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.

• Evox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease

  8/4/2023

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, NY.

• Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

  6/20/2023

  Evox Therapeutics Ltd, a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain engineering and manufacturing rights associated with it.

• Evox Therapeutics Granted Key US Exosome Purification Patent to Further Expand Its Leading Patent Portfolio

  5/17/2023

  Evox Therapeutics Ltd today announced that the Company has been granted another US patent adding to its growing manufacturing IP portfolio.

• Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics

  5/12/2023

  Evox Therapeutics Ltd, a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles Annual Meeting, May 17-21, 2023, in Seattle.

• Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

  5/26/2022

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announced advances in exosome engineering, manufacturing and tissue targeting at the International Society for Extracellular Vesicles Annual Meeting, on May 25 to 29, 2022, in Lyon, France.

• Evox Therapeutics to Present at the 2022 Jefferies Healthcare Conference

  5/24/2022

  Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will participate in the 2022 Jefferies Healthcare Conference June 8-10, 2022. Antonin de Fougerolles, Ph.D., Chief Executive Officer of Evox Therapeutics, will present on Friday, June 10 at 11:30 a.m. EDT and will host 1x1 meetings at and around the conference in New York.

• Evox Therapeutics Announces Data Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

  5/19/2022

  Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced titles of nine abstracts to be presented as oral presentations and posters at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France.

• International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics’ Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution

  5/9/2022

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy 2022 Meeting, May 4 to 7, in San Francisco.

• 

  BioSpace Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena Oncology

  4/15/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Evox Therapeutics Appoints Peter Jones as Vice President of CMC

  4/14/2022

  Evox Therapeutics Ltd announces the appointment of Peter Jones as Vice President of CMC.

• Landmark paper highlights Evox Therapeutics' cutting edge exosome engineering approach for enhanced surface display of biologics

  10/7/2021

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that it has, in close collaboration with one of its co-founder's lab at the Karolinska Institute, published a landmark paper in Nature Biomedical Engineering outlining the engineering of exosomes for surface display of proteins.

• 

  Money on the Move: February 17-23

  2/24/2021

  Life sciences companies across the globe are raking in investment dollars to advance drug programs.

• Evox Therapeutics completes £69.2 million Series C financing

  2/18/2021

  Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform

• John McHutchison joins the Board of Evox Therapeutics

  1/18/2021

  Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that John McHutchison has joined its Board of Directors.

• Evox Therapeutics expands its existing exosome patent portfolio

  11/24/2020

  Grant protects a proprietary approach that enables luminal loading of soluble therapeutic proteins into exosomes

• Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

  11/17/2020

  Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

• Evox Therapeutics appoints Dr David Lowe as Vice President of Research

  10/13/2020

  Further growth of leadership team with hire of highly experienced drug developer

• Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics

  7/15/2020

  Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office.

• Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

  6/9/2020

  Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders   [09-June-2020]   OXFORD, England , June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreeme